Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
Pancreatic ductal adenocarcinoma (PDAC) is presently one of the cancers with the worst survival rates. The current treatment options for PDAC are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of PDAC. Based on next-generation sequencing (NGS), we first...
Main Authors: | Fan Meng, Le Lu, Yuan Tan, Qianqian Duan, Hongwei Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.757965/full |
Similar Items
-
KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas
by: Aida Catic, et al.
Published: (2020-10-01) -
Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
by: Xiao Z, et al.
Published: (2020-05-01) -
Talin-KANK1 interaction controls the recruitment of cortical microtubule stabilizing complexes to focal adhesions
by: Benjamin P Bouchet, et al.
Published: (2016-07-01) -
Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
by: Jeongwan Kang, et al.
Published: (2020-09-01) -
NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine
by: Federica Zito Marino, et al.
Published: (2020-05-01)